Our expertise blends traditional biotechnology with emerging areas of informatics and molecular assays. We build end-to-end solutions with quick turn around to set-up world class diagnostic labs.
Early detection and timely intervention increases chances of successful treatment in a number of health conditions. Delayed diagnosis often leads to increased patient complications, higher cost of treatment and poor outcome.
In cancer, early detection includes early stage diagnosis, screening asymptomatic individuals, and detecting cancer relapse. Beyond oncology, this impacts monitoring patients post organ transplants, diagnosing pre-natal chromosomal abnormalities and early detection of neurodegenerative disorders.
The goal is to detect malignancy at the earliest possible instance when it is easiest to intervene and treat. Five year survival is greater than 80% for oral, breast, cervical, lung and most cancers, when detected in stage I. Treatment costs are order of magnitude lower when cancer is detected early. Hence cancer screening in an otherwise asymptomatic population is a key public health necessity especially in India. Cancer screening requires development of ultra sensitive assays or /and orthogonal AI/ML driven image analysis platforms, which are non invasive and cost effective solutions.
An early detection of graft rejection in organ transplant can save lives. 20-50% of heart transplant patients face rejection within the first year. In all cases, rejection starts silently, almost without a symptom. Most definitive diagnosis for graft rejection is through biopsy which itself poses a risk. A non invasive blood / urine based test that can detect DNA fragments of the transplant donor, in the body fluid of the recipient, holds promise to detect rejection ahead of time before symptoms arise.
Prediction of adverse pre-natal outcomes can significantly impact the well being of both mother and child. AI, ML and newly emerged affective computing (AC) as well as the completely orthogonal tools like the profile of vaginal microbiome can help clinical decision making such as labor vs c-section, identify patients such as those at high risk of pre-eclampsia or pre-term labor.
It has been demonstrated that the onset of Alzheimer, Parkinson’s, Huntington’s and other neurodegenerative diseases precedes clinical manifestation by 15 to 20 years. Circulating nucleic acids as well a functional imaging may assist early differential diagnosis as well as prognostication. As new therapies emerge, not only are these more effective in early diseases but trials benefit from early and accurate segregation of subjects based on inclusion and exclusion criteria.